Constantine S. Tam

30.3k citations

412 papers · 9.1k · 6 hit papers · h-index 51

Impact in

Genetics top 0.02%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 338
- Chronic Lymphocytic Leukemia Research 323
Pathology and Forensic Medicine 199
- Lymphoma Diagnosis and Treatment 196

Co-authors: Michael J. Keating (38 shared papers)John F. Seymour (82 shared papers)William G. Wierda (51 shared papers)Hagop M. Kantarjian (22 shared papers)David Westerman (43 shared papers)Andrew W. Roberts (43 shared papers)Susan Lerner (21 shared papers)Jörge E. Cortes (13 shared papers)
Journals: Blood (124 papers)Journal of Clinical Oncology (46 papers)Hematological Oncology (28 papers)Blood Advances (23 papers)HemaSphere (17 papers)
Partner nations: Australia United States Italy

In The Last Decade

Constantine S. Tam

377 papers receiving 8.9k citations

Constantine S. Tam's Hit Papers

6 papers align trajectories log scale

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort 2022 · 139 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Blood
2019 American Journal of Hematology
2018 New England Journal of Medicine
2018 Cancer Discovery
2015 Blood
2008 Blood

Peers

Countries citing papers authored by Constantine S. Tam

Since Specialization

Citations

This map shows the geographic impact of Constantine S. Tam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constantine S. Tam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constantine S. Tam more than expected).

Fields of papers citing papers by Constantine S. Tam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constantine S. Tam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constantine S. Tam. The network helps show where Constantine S. Tam may publish in the future.

Co-authors

The 25 scholars most cited alongside Constantine S. Tam, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Constantine S. Tam Line = papers co-authored together Constantine S. Tam links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 412 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood ·Constantine S. Tam, Susan O’Brien, William G. Wierda, Hagop M. Kantarjian, Sijin Wen, Kim‐Anh Do, Deborah A. Thomas, Jörge E. Cortes, Susan Lerner, Michael J. Keating Hit paper breakdown →	2008	509
2	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia Blood ·Philip A. Thompson, Constantine S. Tam, Susan O’Brien, William G. Wierda, Francesco C. Stingo, William Plunkett, Susan Smith, Hagop M. Kantarjian, Emil J. Freireich, Michael J. Keating Hit paper breakdown →	2015	356
3	Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma American Journal of Hematology ·Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach Hit paper breakdown →	2019	318
4	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia Cancer Discovery ·Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts Hit paper breakdown →	2018	284
5	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma New England Journal of Medicine ·Constantine S. Tam, Mary Ann Anderson, Christiane Pott, Rishu Agarwal, Sasanka M. Handunnetti, Rodney J. Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David Westerman, Stephen Lade, Martin Dreyling, Sarah‐Jane Dawson, Mark A. Dawson, John F. Seymour, Andrew W. Roberts Hit paper breakdown →	2018	279
6	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia New England Journal of Medicine ·Meletios Α. Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Lorella Orsucci, M. Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske	2018	239
7	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions Blood ·M Levade, Elodie David, Cédric Garcia, Pierre Laurent, Sarah Cadot, Anne‐Sophie Michallet, Jean‐Claude Bordet, Constantine S. Tam, Piérre Siè, Loïc Ysebaert, Bernard Payrastre	2014	233
8	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism Blood ·Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine S. Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Éric Ghigo, Ian J. Majewski, David Segal, Sari L. Heitner Enschede, David C.S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts	2016	220
9	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation Leukemia ·S Kamel, Linda W. Horton, Loïc Ysebaert, M Levade, Kate Burbury, Seng‐Lai Tan, M. Cole‐Sinclair, John Reynolds, Robin Filshie, S. Schischka, Amit Khot, Shahneen Sandhu, Michael J. Keating, Harshal Nandurkar, Constantine S. Tam	2014	170
10	Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy Blood ·Charlotte Hughes, Amit Khot, Christopher McCormack, Stephen Lade, David Westerman, Robert Twigger, Odette Buelens, Kate Newland, Constantine S. Tam, Michael Dickinson, Gail Ryan, David Ritchie, Colin Wood, H. Miles Prince	2014	156
11	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort Blood ·Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia Hit paper breakdown →	2022	139
12	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood ·Constantine S. Tam, Roland L. Bassett, Celina Ledesma, Martin Körbling, Amin Alousi, Chitra Hosing, Partow Kebraei, Robyn K. Harrell, Gabriela Rondón, Sergio Giralt, Paolo Anderlini, Uday Popat, Barbara Pro, Barry I. Samuels, Frederick Hagemeister, L. Jeffrey Medeiros, Richard E. Champlin, Issa F. Khouri	2009	135
13	The natural history and treatment outcome of blast phase BCR-ABL− myeloproliferative neoplasms Blood ·Constantine S. Tam, Roberto M. Nussenzveig, Uday Popat, Carlos E. Bueso‐Ramos, Deborah A. Thomas, (unknown), Richard E. Champlin, Stefan E. Ciurea, Taghi Manshouri, Sherry M. Pierce, Hagop M. Kantarjian, Srđan Verstovšek	2008	123
14	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience Blood ·Constantine S. Tam, Tait D. Shanafelt, William G. Wierda, Lynne V. Abruzzo, Daniel L. Van Dyke, Susan O’Brien, Alessandra Ferrajoli, Susan Lerner, Alice Lynn, Neil E. Kay, Michael J. Keating	2009	114
15	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax Blood ·Mary Ann Anderson, Constantine S. Tam, Thomas E. Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David C.S. Huang, John F. Seymour, Andrew W. Roberts	2017	112
16	Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study British Journal of Haematology ·Philip A. Thompson, Vincent Lévy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loïc Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, Florence Cymbalista	2016	97
17	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial Blood ·Constantine S. Tam, Andrew Grigg, Stephen Opat, Matthew Ku, Michael Gilbertson, Mary Ann Anderson, John F. Seymour, (unknown), Carmen DiCorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, Lusong Luo, Ling Xue, Andrew W. Roberts	2015	96
18	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Blood ·Elias Jabbour, Daniel M. Jones, Hagop M. Kantarjian, Susan O’Brien, Constantine S. Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, Jörge E. Cortes	2009	94
19	Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Journal of Clinical Oncology ·Constantine S. Tam, Hagop M. Kantarjian, Jörge E. Cortes, Alice Lynn, Sherry Pierce, Lingsha Zhou, Michael J. Keating, Deborah A. Thomas, Srđan Verstovšek	2009	93
20	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014 Internal Medicine Journal ·Shaun Fleming, Costas K. Yannakou, Gabrielle M. Haeusler, Julia Clark, Andrew Grigg, Christopher H. Heath, Ashish Bajel, Sebastiaan J. van Hal, Sharon C.‐A. Chen, Samuel T. Milliken, C. Orla Morrissey, Constantine S. Tam, Jeff Szer, Robert Weinkove, Monica A. Slavin	2014	93

About Constantine S. Tam

Constantine S. Tam is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Immunology, having authored 412 papers that have together received 9.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (323 papers), Lymphoma Diagnosis and Treatment (196 papers), Chronic Myeloid Leukemia Treatments (75 papers), Immunodeficiency and Autoimmune Disorders (52 papers), CAR-T cell therapy research (39 papers), Acute Lymphoblastic Leukemia research (35 papers), Viral-associated cancers and disorders (29 papers) and Advanced Breast Cancer Therapies (20 papers). The work is most often cited by research in Genetics (6.6k citations), Pathology and Forensic Medicine (4.6k citations), Hematology (2.3k citations), Immunology (1.9k citations) and Oncology (1.7k citations). Constantine S. Tam has collaborated with scholars based in Australia, United States and Italy. Frequent co-authors include Michael J. Keating, John F. Seymour, William G. Wierda, Hagop M. Kantarjian, David Westerman, Andrew W. Roberts, Susan Lerner, Jörge E. Cortes, Susan O’Brien and Mary Ann Anderson. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Blood Advances and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Constantine S. Tam

Impact in

Papers in i

In The Last Decade

Constantine S. Tam

Constantine S. Tam's Hit Papers

Peers

Countries citing papers authored by Constantine S. Tam

Fields of papers citing papers by Constantine S. Tam

All Works

About Constantine S. Tam

Explore authors with similar magnitude of impact

Papers in